Endocrine Abstracts

Differentiated thyroid cancer (DTC) is the most common endocrine malignancy. Despite most patients having an initial good prognosis, some patients progress and become resistant to standard radioiodine treatment. Importantly, effective markers or therapies are not yet available. Many of these patients present tumours with high levels of dedifferentiation, having lost some or most of their thyrocyte-specific features. As DTC patients present low levels of mutations, epigenetics ...

Background: Poorly differentiated (PDTCs), anaplastic (ATCs) thyroid cancers and few well differentiated thyroid cancers (WDTC) are particularly aggressive and refractory to all treatments, including tyrosine kinase inhibitors (TKIs). Since in other tumors, TP53 mutations are related to a poorer response to TKIs treatment, we aimed to investigate the impact of TP53 mutations on thyroid cancer response to Lenvatinib (LEN) treatment.Metho...

Objectives: The oncogene UHRF1 (Ubiquitin-like with PHD and RING Finger domains 1) codifies for a nuclear protein which primarily acts as epigenetic regulator during the replication phase, but also as cycle cell regulator upon DNA damage. The over-expression of this oncogene has been documented in several human cancers, including thyroid cancers (TCs), and correlates with both tumour aggressiveness and response to treatment. Regarding TC, scanty data are available on ...

Background: Tumour heterogeneity and evolution present significant challenges in advanced thyroid cancers, contributing to treatment resistance and disease progression. NOMINATE (NCT05837260) is a multicentre, prospective biological sampling study which aims to investigate the genomic diversity of thyroid cancers and assess the utility of circulating tumour DNA (ctDNA) for delineating evolutionary forces driving treatment failure and resistance. We present our latest progress ...

Alterations in DICER1 and DGCR8 have been observed in benign thyroid manifestations, well-differentiated and recently reported in poorly-differentiated thyroid cancers (PDTC). The involvement of 2 miRNA biogenesis genes in benign and malignant thyroid tumors highlights the key role of miRNAs in the thyroid gland.Objectives: To determine the deregulated miRNAs involved in benign and malignant thyroid tumors associated with miRNA biogenes...